Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Christina M. Arieta"'
Autor:
Asaf Poran, Dewi Harjanto, Matthew Malloy, Christina M. Arieta, Daniel A. Rothenberg, Divya Lenkala, Marit M. van Buuren, Terri A. Addona, Michael S. Rooney, Lakshmi Srinivasan, Richard B. Gaynor
Publikováno v:
Genome Medicine, Vol 12, Iss 1, Pp 1-15 (2020)
Abstract Background The ongoing COVID-19 pandemic has created an urgency to identify novel vaccine targets for protective immunity against SARS-CoV-2. Early reports identify protective roles for both humoral and cell-mediated immunity for SARS-CoV-2.
Externí odkaz:
https://doaj.org/article/9f61d50420b745d5900a6a515483100a
Autor:
Christina M. Arieta, Yushu Joy Xie, Daniel A. Rothenberg, Huitian Diao, Dewi Harjanto, Shirisha Meda, Krisann Marquart, Byron Koenitzer, Tracey E. Sciuto, Alexander Lobo, Adam Zuiani, Stefanie A. Krumm, Carla Iris Cadima Couto, Stephanie Hein, André P. Heinen, Thomas Ziegenhals, Yunpeng Liu-Lupo, Annette B. Vogel, John R. Srouji, Stephanie Fesser, Kaushik Thanki, Kerstin Walzer, Theresa A. Addona, Özlem Türeci, Uğur Şahin, Richard B. Gaynor, Asaf Poran
Publikováno v:
Cell. 186:2392-2409.e21
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9953902c43ac69914921cbcd7e3eb591
https://doi.org/10.1016/j.cell.2023.04.007
https://doi.org/10.1016/j.cell.2023.04.007
Autor:
Jonathan McGee, Divya Lenkala, Prerna Suri, Gabe S. Sonke, John B. A. G. Haanen, Marit M. van Buuren, Jessica Kohler, Christina M. Arieta, Richard B. Gaynor, C.M. Nijenhuis, Mark DeMario, Brian C. McCarthy, Maarje Rohaan, Susan Hannes, Dewi Harjanto, Daniel Kallin, Paul J. Turcott, Diana Velez, Shirisha Meda
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A212-A212
BackgroundNeoantigens are tumor-specific antigens that are important in the anti-tumor immune response. These antigens are not subject to central immune tolerance and are therefore potentially more immunogenic than tumor-associated antigens. Here, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::215e3c2a210bcb14e631fa72d8e74e8d
https://doi.org/10.1136/jitc-2021-sitc2021.201
https://doi.org/10.1136/jitc-2021-sitc2021.201
Autor:
Terri A. Addona, Christina M. Arieta, Richard B. Gaynor, Dewi Harjanto, Yusuf Nasrullah, Dominik Barthelme, Jeff Hammerbacher, Matthew Malloy, Edward F. Fritsch, Rob C. Oslund, Prerna Suri, Asaf Poran, Joel Greshock, Christopher D. McGann, Daniel A. Rothenberg, Sagar Chhangawala, Scott P. Goulding, Alex Rubinsteyn, Tyler Colson, Gibran Nasir, Amanda L. Creech, Ying S. Ting, Michael S. Rooney, Diana Velez, Jennifer G. Abelin, Lia R. Serrano
Publikováno v:
Immunity. 51(4)
Summary Increasing evidence indicates CD4+ T cells can recognize cancer-specific antigens and control tumor growth. However, it remains difficult to predict the antigens that will be presented by human leukocyte antigen class II molecules (HLA-II), h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c95f52d9f13a04c53e86f67e9ba9f826
https://pubmed.ncbi.nlm.nih.gov/33567264
https://pubmed.ncbi.nlm.nih.gov/33567264
Autor:
Terri A. Addona, Asaf Poran, Matthew Malloy, Michael S. Rooney, Daniel A. Rothenberg, Divya Lenkala, Lakshmi Srinivasan, Dewi Harjanto, Christina M. Arieta, Richard B. Gaynor, Marit M. van Buuren
Publikováno v:
Clinical Cancer Research. 26:S03-02
The ongoing COVID-19 pandemic has created an urgency to identify novel vaccine targets for protective immunity against SARS-CoV-2. Consistent with observations for the closely related SARS-CoV, early reports identify a protective role for both humora
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::733cc25df24b2462db2b9c0f451fe449
https://doi.org/10.1158/1557-3265.covid-19-s03-02
https://doi.org/10.1158/1557-3265.covid-19-s03-02
Autor:
Rob C. Oslund, Dewi Harjanto, Jennifer G. Abelin, Jeff Hammerbacher, Yusuf Nasrullah, Sagar Chhangawala, Lia R. Serrano, Alex Rubinsteyn, Gibbs Nasir, Amanda L. Creech, Ying S. Ting, Christopher D. McGann, Asaf Poran, Edward F. Fritsch, Michael S. Rooney, Tyler Colson, Dominik Barthelme, Daniel A. Rothenberg, Scott P. Goulding, Prerna Suri, Terri A. Addona, Matthew Malloy, Christina M. Arieta, Richard B. Gaynor, Diana Velez
Publikováno v:
Cancer Immunology Research. 8:B23-B23
While tumor-reactive CD4+ T cells have been associated with effective immunotherapy responses, accurate prediction of MHC class II-restricted ligands remains a challenge, limiting our ability to harness CD4+ immunity for cancer therapy. To this end,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ce52d357655b53bffea5e8a720cf705
https://doi.org/10.1158/2326-6074.tumimm19-b23
https://doi.org/10.1158/2326-6074.tumimm19-b23